In a research report made available to the public on Thursday, the analysts at StockNews.com discussed Fresenius Medical Care AG & Co KGaA as the focus of their attention (NYSE: FMS).
The company recommended to potential investors that they “purchase” the stock.
At the start of trading on Thursday, the NYSE FMS set the opening price at $19.58.
The moving average for the stock over the past 50 days is $18.98, the moving average over the past 200 days is $16.54the past 50 days is $18.98, and the moving average over the past 200 days is $16.54.
The quick ratio is 0.91, the current ratio is 1.27, and the debt-to-equity ratio is 0.46.
All of these numbers are relative to the total amount of debt.
All these figures should be interpreted in light of the overall sum owed. Over the previous twelve months, the share price of Fresenius Medical Care AG & Co KGaA ranged from a low of $12.78 to an all-time high of $34.65 at various points.
The share price-to-earnings ratio for the stock is currently 16.32, with a beta value of 1.00.
The stock’s current market value is 11.49 billion dollars.
FMS has been the subject of discussion among many additional research professionals. Jefferies Financial Group rated Fresenius Medical Care AG & Co KGaA’s stock as having an “underperform” status in a report on the company’s performance released on January 2.
Before this rating, a recommendation to “buy” the company’s stock had been made.
In addition, the price target they had established for the company was lowered from $14.00 to $11.70. Sanford C.
Bernstein published a research note on March 7 announcing that the firm will initiate coverage of shares of Fresenius Medical Care AG & Co KGaA.
The announcement was made public.
They ranked the company as having “market perform” as its overall performance in the market.
The recommendation to “hold” Fresenius Medical Care AG & Co KGaA’s stock was changed to “reduce” in a research report published on March 7.
This marked a change from the previous recommendation to “hold” the company’s stock.
In a report released on Thursday, February 23, Truist Financial upgraded Fresenius Medical Care AG & Co KGaA from a “hold” rating to a “buy” rating and raised their target price on the stock from $17.00 to $22.00.
The report was titled “Fresenius Medical Care AG & Co KGaA Research Update.” The stock comes with a recommendation to sell from four equity research analysts, a recommendation to hold it from six, and a recommendation to buy it from one.
According to the information that Bloomberg provided, the current consensus regarding the company’s stock is to maintain a “Hold” position, and the average price target is $28.20.
Several hedge funds have been active buyers and sellers of FMS shares over the past few months.
Pzena Investment Management LLC’s ownership of Fresenius Medical Care AG & Co KGaA stock increased by 85.4% during the fourth quarter due to the company’s acquisition of additional shares. Following the acquisition of 11,209,015 additional company shares during the most recent fiscal quarter, Pzena Investment Management LLC now holds 24,332,192 shares in its portfolio.
The value of the company’s stock on the market currently is $397,588,000.
During the last three months of 2018, Arrowstreet Capital Limited Partnership held Fresenius Medical Care AG & Co KGaA for a larger percentage than in the past.
This increase was 77.1% higher than the previous percentage.
Arrowstreet Capital Limited Partnership now holds 1,570,817 shares of the company’s stock, which has a market value of $25,667,000 after purchasing an additional 683,851 shares during the most recent fiscal quarter.
These shares were acquired for a total cost of $25,667,000.
Millennium Management LLC initiated a fresh stake in Fresenius Medical Care AG & Co KGaA during the second fiscal quarter.
Approximately $16,738,000 was exchanged in this business transaction.
During the third quarter, Marshall Wace LLP increased the amount of Fresenius Medical Care AG & Co KGaA stock owned by a percentage of 1,151.7% higher than before.
After purchasing an additional 286,838 shares during the most recent quarter, Marshall Wace LLP now owns 311,743 shares of the company’s stock, which is $4,376,000.
These shares were acquired as a result of the most recent purchase.
Last but not least, during the third quarter, BlackRock INC increased the amount of Fresenius Medical Care AG & Co KGaA stock owned by 240.0%.
This certainly should not be considered the least important development.
BlackRock INC now has 404,730 shares of the company’s stock, valued at a combined total of $5,682,000, after purchasing an additional 285,705 shares during the preceding quarter.
This brings the total number of shares owned by BlackRock INC to 404,730. 5.56 hedge funds and other institutional investors hold a percent of the company’s shares.
Patients who suffer from kidney disease have access to a wide range of products and services thanks to the efforts of Fresenius Medical Care AG & Co KgaA, which is a company.
The company conducts research and development on a wide range of medical products, some of which are associated with the industry of dialysis while other products are not.
It operates commercially not only in the Americas south of the United States but also in Europe, the Asia-Pacific region, and Latin America.